Blood Test Spots Early Breast Cancer at 95%
Blood Test Spots Early Breast Cancer at 95%
Blood Test Spots Early Breast Cancer at 95%
Key points
اہم نکات
मुख्य बातें
- 95% accuracy — that is how well a new experimental blood test spotted early-stage breast cancer in a newly published study, detecting tumours smaller than two centimetres.
- Researchers from the Weizmann Institute and the Hebrew University mapped the epigenetic switches inside breast tumours and found a particularly aggressive group of cells hiding among harmless ones, a pattern that may explain why cancer returns in 20 to 40 percent of cases even after successful treatment.
- Tested on blood from 77 breast cancer patients and 30 healthy women, the test could help doctors find the disease earlier and judge the risk of it coming back.
- 95% accuracy — that is how well a new experimental blood test spotted early-stage breast cancer in a newly published study, detecting tumours smaller than two centimetres.
- Researchers from the Weizmann Institute and the Hebrew University mapped the epigenetic switches inside breast tumours and found a particularly aggressive group of cells hiding among harmless ones, a pattern that may explain why cancer returns in 20 to 40 percent of cases even after successful treatment.
- Tested on blood from 77 breast cancer patients and 30 healthy women, the test could help doctors find the disease earlier and judge the risk of it coming back.
- 95% accuracy — that is how well a new experimental blood test spotted early-stage breast cancer in a newly published study, detecting tumours smaller than two centimetres.
- Researchers from the Weizmann Institute and the Hebrew University mapped the epigenetic switches inside breast tumours and found a particularly aggressive group of cells hiding among harmless ones, a pattern that may explain why cancer returns in 20 to 40 percent of cases even after successful treatment.
- Tested on blood from 77 breast cancer patients and 30 healthy women, the test could help doctors find the disease earlier and judge the risk of it coming back.
95% accuracy — that is how well a new experimental blood test spotted early-stage breast cancer in a newly published study, detecting tumours smaller than two centimetres. Researchers from the Weizmann Institute and the Hebrew University mapped the epigenetic switches inside breast tumours and found a particularly aggressive group of cells hiding among harmless ones, a pattern that may explain why cancer returns in 20 to 40 percent of cases even after successful treatment. Tested on blood from 77 breast cancer patients and 30 healthy women, the test could help doctors find the disease earlier and judge the risk of it coming back. The method is still experimental and needs larger trials before it can be used in clinics.
95% accuracy — that is how well a new experimental blood test spotted early-stage breast cancer in a newly published study, detecting tumours smaller than two centimetres. Researchers from the Weizmann Institute and the Hebrew University mapped the epigenetic switches inside breast tumours and found a particularly aggressive group of cells hiding among harmless ones, a pattern that may explain why cancer returns in 20 to 40 percent of cases even after successful treatment. Tested on blood from 77 breast cancer patients and 30 healthy women, the test could help doctors find the disease earlier and judge the risk of it coming back. The method is still experimental and needs larger trials before it can be used in clinics.
95% accuracy — that is how well a new experimental blood test spotted early-stage breast cancer in a newly published study, detecting tumours smaller than two centimetres. Researchers from the Weizmann Institute and the Hebrew University mapped the epigenetic switches inside breast tumours and found a particularly aggressive group of cells hiding among harmless ones, a pattern that may explain why cancer returns in 20 to 40 percent of cases even after successful treatment. Tested on blood from 77 breast cancer patients and 30 healthy women, the test could help doctors find the disease earlier and judge the risk of it coming back. The method is still experimental and needs larger trials before it can be used in clinics.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।